GB201007357D0 - Conjugated factor VIII - Google Patents

Conjugated factor VIII

Info

Publication number
GB201007357D0
GB201007357D0 GBGB1007357.5A GB201007357A GB201007357D0 GB 201007357 D0 GB201007357 D0 GB 201007357D0 GB 201007357 A GB201007357 A GB 201007357A GB 201007357 D0 GB201007357 D0 GB 201007357D0
Authority
GB
United Kingdom
Prior art keywords
factor viii
conjugated factor
conjugated
viii
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1007357.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LEVERTON LICENCE HOLDINGS Ltd
Original Assignee
LEVERTON LICENCE HOLDINGS Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42289987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB201007357(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by LEVERTON LICENCE HOLDINGS Ltd filed Critical LEVERTON LICENCE HOLDINGS Ltd
Priority to GBGB1007357.5A priority Critical patent/GB201007357D0/en
Publication of GB201007357D0 publication Critical patent/GB201007357D0/en
Priority to SG2012077087A priority patent/SG184906A1/en
Priority to US13/643,287 priority patent/US20130150302A1/en
Priority to BR112012027590A priority patent/BR112012027590A2/pt
Priority to PH1/2012/502150A priority patent/PH12012502150A1/en
Priority to NZ603939A priority patent/NZ603939A/xx
Priority to MYPI2012004710A priority patent/MY160922A/en
Priority to AU2011247147A priority patent/AU2011247147B2/en
Priority to PCT/GB2011/000662 priority patent/WO2011135307A1/en
Priority to CA2797058A priority patent/CA2797058A1/en
Priority to AP2012006575A priority patent/AP2012006575A0/xx
Priority to JP2013506735A priority patent/JP5870088B2/ja
Priority to KR1020127031386A priority patent/KR20130055619A/ko
Priority to MX2012012683A priority patent/MX2012012683A/es
Priority to CN2011800218881A priority patent/CN102939108A/zh
Priority to PE2012002104A priority patent/PE20130254A1/es
Priority to EA201290938A priority patent/EA201290938A1/ru
Priority to EP11719040A priority patent/EP2563402A1/en
Priority to RU2012144555/15A priority patent/RU2012144555A/ru
Priority to HK13100809.6A priority patent/HK1173946B/xx
Priority to GB201220667A priority patent/GB2492935B8/en
Priority to IL222566A priority patent/IL222566A/en
Priority to NI201200160A priority patent/NI201200160A/es
Priority to CL2012003039A priority patent/CL2012003039A1/es
Priority to CR20120579A priority patent/CR20120579A/es
Priority to ZA2012/08989A priority patent/ZA201208989B/en
Priority to ECSP12012314 priority patent/ECSP12012314A/es
Priority to CO12216949A priority patent/CO6660443A2/es
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
GBGB1007357.5A 2010-04-30 2010-04-30 Conjugated factor VIII Ceased GB201007357D0 (en)

Priority Applications (28)

Application Number Priority Date Filing Date Title
GBGB1007357.5A GB201007357D0 (en) 2010-04-30 2010-04-30 Conjugated factor VIII
HK13100809.6A HK1173946B (en) 2010-04-30 2011-04-28 Polyethylene glycol conjugated blood coagulation factor viii
GB201220667A GB2492935B8 (en) 2010-04-30 2011-04-28 Polyethylene glycol conjugated blood coagulation factor VIII
MX2012012683A MX2012012683A (es) 2010-04-30 2011-04-28 Factor viii conjugado para coagulacion de la sangre.
CN2011800218881A CN102939108A (zh) 2010-04-30 2011-04-28 缀合的凝血因子viii
BR112012027590A BR112012027590A2 (pt) 2010-04-30 2011-04-28 conjugado de fator viii de coagulação sanguínea
PH1/2012/502150A PH12012502150A1 (en) 2010-04-30 2011-04-28 Conjugated blood coagulation factor viii
NZ603939A NZ603939A (en) 2010-04-30 2011-04-28 Conjugated blood coagulation factor viii
MYPI2012004710A MY160922A (en) 2010-04-30 2011-04-28 Polyethylene glycol conjugated blood coagulation factor vii
AU2011247147A AU2011247147B2 (en) 2010-04-30 2011-04-28 Conjugated blood coagulation Factor VIII
PCT/GB2011/000662 WO2011135307A1 (en) 2010-04-30 2011-04-28 Conjugated blood coagulation factor viii
CA2797058A CA2797058A1 (en) 2010-04-30 2011-04-28 Conjugated blood coagulation factor viii
AP2012006575A AP2012006575A0 (en) 2010-04-30 2011-04-28 Conjugated blood coagulation factor VIII
JP2013506735A JP5870088B2 (ja) 2010-04-30 2011-04-28 共役血液凝固第ｖｉｉｉ因子
KR1020127031386A KR20130055619A (ko) 2010-04-30 2011-04-28 접합된 혈액 응고 인자 viii
SG2012077087A SG184906A1 (en) 2010-04-30 2011-04-28 Conjugated blood coagulation factor viii
US13/643,287 US20130150302A1 (en) 2010-04-30 2011-04-28 Conjugated blood coagulation factor viii
PE2012002104A PE20130254A1 (es) 2010-04-30 2011-04-28 Factor viii conjugado para coagulacion de la sangre
EA201290938A EA201290938A1 (ru) 2010-04-30 2011-04-28 Конъюгированный фактор свертывания крови viii
EP11719040A EP2563402A1 (en) 2010-04-30 2011-04-28 Conjugated blood coagulation factor viii
RU2012144555/15A RU2012144555A (ru) 2010-04-30 2011-04-28 Конъюгированный фактор свертывания крови viii
IL222566A IL222566A (en) 2010-04-30 2012-10-21 Blood clotting factor viii conjugate
CL2012003039A CL2012003039A1 (es) 2010-04-30 2012-10-29 Polietilenglicol conjugado a factor viii mediante un grupo conector; composicion farmaceutica que comprende dicho polietilenglicol conjugado; uso de dicha composicion para tratamiento de una enfermedad o trauma de la coagulacion de la sangre.
NI201200160A NI201200160A (es) 2010-04-30 2012-10-29 Factor viii conjugado para coagulación de la sangre.
CR20120579A CR20120579A (es) 2010-04-30 2012-11-14 Factor viii conjugado para coagulación de la sangre
ZA2012/08989A ZA201208989B (en) 2010-04-30 2012-11-28 Conjugated blood coagulation factor viii
ECSP12012314 ECSP12012314A (es) 2010-04-30 2012-11-28 Factor viii conjugado para coagulación de la sangre
CO12216949A CO6660443A2 (es) 2010-04-30 2012-11-29 Factor viii conjugado para coagulación de la sangre a polietilenglicol (peg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1007357.5A GB201007357D0 (en) 2010-04-30 2010-04-30 Conjugated factor VIII

Publications (1)

Publication Number Publication Date
GB201007357D0 true GB201007357D0 (en) 2010-06-16

Family

ID=42289987

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB1007357.5A Ceased GB201007357D0 (en) 2010-04-30 2010-04-30 Conjugated factor VIII
GB201220667A Expired - Fee Related GB2492935B8 (en) 2010-04-30 2011-04-28 Polyethylene glycol conjugated blood coagulation factor VIII

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB201220667A Expired - Fee Related GB2492935B8 (en) 2010-04-30 2011-04-28 Polyethylene glycol conjugated blood coagulation factor VIII

Country Status (26)

Country Link
US (1) US20130150302A1 (enExample)
EP (1) EP2563402A1 (enExample)
JP (1) JP5870088B2 (enExample)
KR (1) KR20130055619A (enExample)
CN (1) CN102939108A (enExample)
AP (1) AP2012006575A0 (enExample)
AU (1) AU2011247147B2 (enExample)
BR (1) BR112012027590A2 (enExample)
CA (1) CA2797058A1 (enExample)
CL (1) CL2012003039A1 (enExample)
CO (1) CO6660443A2 (enExample)
CR (1) CR20120579A (enExample)
EA (1) EA201290938A1 (enExample)
EC (1) ECSP12012314A (enExample)
GB (2) GB201007357D0 (enExample)
IL (1) IL222566A (enExample)
MX (1) MX2012012683A (enExample)
MY (1) MY160922A (enExample)
NI (1) NI201200160A (enExample)
NZ (1) NZ603939A (enExample)
PE (1) PE20130254A1 (enExample)
PH (1) PH12012502150A1 (enExample)
RU (1) RU2012144555A (enExample)
SG (1) SG184906A1 (enExample)
WO (1) WO2011135307A1 (enExample)
ZA (1) ZA201208989B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2101821T3 (da) 2006-12-15 2014-10-06 Baxter Healthcare Sa Faktor VIIA-(poly)sialinsyre-konjugat med forlænget halveringstid in vivo
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
EP3081233B1 (en) 2009-07-27 2020-12-23 Baxalta GmbH Glycopolysialylation of proteins other than blood coagulation proteins
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
BR112012001814A8 (pt) 2009-07-27 2018-02-06 Baxalta GmbH Conjugados de proteína de coagulação sanguínea
ES2800983T3 (es) 2010-12-22 2021-01-07 Baxalta GmbH Materiales y métodos para conjugar un derivado de ácido graso soluble en agua con una proteína
HK1200695A1 (en) * 2012-04-16 2015-08-14 Cantab Biopharmaceuticals Patents Limited Optimised subcutaneous therapeutic agents
GB201417589D0 (en) 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
CN117467019A (zh) 2018-05-18 2024-01-30 郑州晟斯生物科技有限公司 改进的fviii融合蛋白及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1596887B1 (en) * 2003-02-26 2022-03-23 Nektar Therapeutics Polymer-factor viii moiety conjugates
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
DK2371856T3 (en) * 2004-11-12 2022-08-08 Bayer Healthcare Llc Site-directed modifikation af FVIII
AU2005322067B8 (en) * 2004-12-27 2012-07-26 Takeda Pharmaceutical Company Limited Polymer-von Willebrand factor-conjugates
WO2007126808A1 (en) * 2006-03-31 2007-11-08 Baxter International Inc Pegylated factor viii
US20100239517A1 (en) 2007-10-09 2010-09-23 Stephen Brocchini Novel conjugated proteins and peptides
KR20110016440A (ko) * 2008-04-24 2011-02-17 셀틱 파르마 피이지 엘티디. 연장된 반감기를 가진 제 ⅰⅹ 인자 접합체
ES2560807T3 (es) 2008-07-21 2016-02-22 Polytherics Limited Nuevos reactivos y procedimiento de conjugación de moléculas biológicas
GB0912485D0 (en) * 2009-07-17 2009-08-26 Polytherics Ltd Improved conjugation method

Also Published As

Publication number Publication date
IL222566A (en) 2017-12-31
GB201220667D0 (en) 2013-01-02
ZA201208989B (en) 2014-02-26
AU2011247147A1 (en) 2013-01-10
EA201290938A1 (ru) 2013-04-30
KR20130055619A (ko) 2013-05-28
WO2011135307A1 (en) 2011-11-03
MX2012012683A (es) 2013-04-03
BR112012027590A2 (pt) 2016-08-09
US20130150302A1 (en) 2013-06-13
GB2492935B8 (en) 2014-10-29
AU2011247147B2 (en) 2014-09-18
GB2492935B (en) 2014-04-30
NI201200160A (es) 2013-04-19
HK1173946A1 (en) 2013-05-31
GB2492935A8 (en) 2014-10-29
CN102939108A (zh) 2013-02-20
RU2012144555A (ru) 2014-06-10
CL2012003039A1 (es) 2014-01-24
PE20130254A1 (es) 2013-03-16
EP2563402A1 (en) 2013-03-06
MY160922A (en) 2017-03-31
PH12012502150A1 (en) 2013-02-04
NZ603939A (en) 2013-08-30
GB2492935A (en) 2013-01-16
JP5870088B2 (ja) 2016-02-24
SG184906A1 (en) 2012-11-29
CR20120579A (es) 2013-04-25
AP2012006575A0 (en) 2012-12-31
CA2797058A1 (en) 2011-11-03
ECSP12012314A (es) 2013-05-31
CO6660443A2 (es) 2013-04-30
JP2013525414A (ja) 2013-06-20
IL222566A0 (en) 2012-12-31

Similar Documents

Publication Publication Date Title
AP3107A (en) 5-Alkynyl-pyrimidines
GB201011143D0 (en) Dispensers
ZA201300032B (en) Tetrahydrocarboline derivative
AU334476S (en) Dispenser
GB201011144D0 (en) Dispensers
GB201007356D0 (en) Conjugated factor VIIa
PL2640598T3 (pl) Izolator sekcyjny
ZA201303887B (en) 2-carboxamide-4-piperazinyl-benzofuran derivative
EP2571358A4 (en) COMBINATION
AU335331S (en) Dispenser
PL2628733T3 (pl) Pochodna acylobenzenu
EP2572199A4 (en) COMBINATION
GB2476947B (en) Extended railway point
PT2533676E (pt) Processo de comando de uma célula de trabalho automatizada
PL2569095T3 (pl) Dozownik
AU335332S (en) Dispenser
GB2480547B (en) Dispenser
EP2654755A4 (en) COMBINATION
EP2603078A4 (en) COMBINATION
AU4536P (en) TB01 Tibouchina urvilleana
AU4932P (en) FlatwaxpinkGL Chamelaucium uncinatum
AU4937P (en) FlatinsulGL Myoporum insulare
AU4931P (en) FlatwaxDarkGL Chamelaucium uncinatum
AU4822P (en) FlatwaxwhiteGL Chamelaucium uncinatum
GB201007358D0 (en) Conjugated protein C

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)